Halozyme Posts Record $1.4B Revenue, Expands Drug Delivery Portfolio with Key Acquisitions
Event summary
- Halozyme reported full-year 2025 revenue of $1.4B, up 38% YoY, driven by 52% growth in royalty revenue.
- Completed acquisitions of Elektrofi's Hypercon™ technology and Surf Bio's hyperconcentration technology.
- Reiterated 2026 guidance: $1.71B–$1.81B total revenue (22–30% growth), $1.13B–$1.17B royalty revenue (30–35% growth).
- Expanded ENHANZE® partnerships with Takeda, Merus, and Skye Bioscience.
- Janssen secured global approvals for Rybrevant SC and DARZALEX Faspro in key markets.
The big picture
Halozyme's record revenue and strategic acquisitions position it as a key player in drug delivery technology. The company's focus on expanding its ENHANZE® and Hypercon™ portfolios aligns with the biopharma industry's shift toward subcutaneous delivery solutions. The projected $1B+ in royalty revenue for 2026 underscores the durability of its business model, but integration risks and regulatory dynamics remain critical factors.
What we're watching
- Royalty Revenue Growth
- Whether Halozyme can sustain the 30–35% royalty revenue growth projected for 2026, given the reliance on partner product launches.
- Integration Risk
- The pace at which Halozyme integrates Elektrofi and Surf Bio technologies into its portfolio and secures new partnerships.
- Regulatory Dynamics
- How global regulatory approvals for ENHANZE-enabled products will impact Halozyme's long-term royalty stream.
Related topics